Gossamer Bio (GOSS)
NASDAQ:GOSS
Want to see GOSS full AI Analyst Report?
GOSS Stock Chart & Stats
$0.45
-$0.10(-9.01%)
At close: 4:00 PM EST
$0.45
-$0.10(-9.01%)
Day’s Range― - ―
52-Week Range$0.14 - $3.87
Previous CloseN/A
Volume602.63K
Average Volume (3M)13.69M
Market Cap
$81.64M
Enterprise Value$201.24M
Total Cash (Recent Filing)$99.22M
Total Debt (Recent Filing)$202.93M
Price to Earnings (P/E)―
Beta1.47
Next Earnings
Aug 11, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.79
Shares Outstanding488,846,700
10 Day Avg. Volume16,756,970
30 Day Avg. Volume13,693,231
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)-5.77
Price to Sales (P/S)14.62
P/FCF Ratio-4.13
Enterprise Value/Market Cap2.47
Enterprise Value/Revenue3.62
Enterprise Value/Gross Profit3.64
Enterprise Value/Ebitda-1.19
Forecast
1Y Price Target
$5.32Price Target Upside1082.22% Upside
Rating ConsensusHold
Number of Analyst Covering6
EPS Forecast (FY)-0.41
Revenue Forecast (FY)$33.60M
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy & Mechanistic ImagingDemonstrated clinical benefit on 6MWD plus correlated CT FRI mechanistic signals provide substantive source evidence beyond a single endpoint. These durable clinical and imaging data strengthen the scientific case for approval, support labeling/market differentiation, and improve partner/commercial interest over months.
Regulatory Pathway ClarityAn in-person Type B meeting and a clear NDA timetable materially reduce regulatory ambiguity. This sustained procedural visibility supports disciplined resourcing, allows targeted pre-submission remediation, and concentrates management effort on a defined approval runway over the medium term.
Capital Structure RemediationA meaningful reduction and extension of convertible debt materially lowers near-term refinancing pressure and aligns maturities with regulatory milestones. Permanently improving debt tenor and secured financing can increase financial flexibility and reduce immediate liquidity-driven distraction for 2-6 months.
Bears Say
Short Cash Runway & Negative Cash FlowWith cash sufficient only to Q1 2027 and TTM operating cash burn extremely negative, the company faces a persistent funding gap. This structural cash shortfall creates durable execution risk requiring near-term financing or material debt/equity actions that affect strategy and dilution over the medium term.
Eroded Balance Sheet And LeverageNegative equity and material outstanding debt indicate cumulative losses have eroded the capital base. The shrunken asset base and leverage reduce financial flexibility, raise covenant and refinancing risk, and limit the company's ability to absorb setbacks or invest in commercial launch without dilution.
Regulatory Uncertainty From Primary EndpointMissing the prespecified alpha creates a durable regulatory and interpretive uncertainty that can force additional FDA scrutiny, request for further evidence, or narrower label claims. That outcome materially affects approval probability, commercial positioning, and partner interest over the coming regulatory cycle.
Gossamer Bio News
GOSS FAQ
What was Gossamer Bio’s price range in the past 12 months?
Gossamer Bio lowest stock price was $0.14 and its highest was $3.87 in the past 12 months.
What is Gossamer Bio’s market cap?
Gossamer Bio’s market cap is $81.64M.
When is Gossamer Bio’s upcoming earnings report date?
Gossamer Bio’s upcoming earnings report date is Aug 11, 2026 which is in 55 days.
How were Gossamer Bio’s earnings last quarter?
Gossamer Bio released its earnings results on May 18, 2026. The company reported -$0.2 earnings per share for the quarter, missing the consensus estimate of -$0.166 by -$0.034.
Is Gossamer Bio overvalued?
According to Wall Street analysts Gossamer Bio’s price is currently Undervalued.
Does Gossamer Bio pay dividends?
Gossamer Bio does not currently pay dividends.
What is Gossamer Bio’s EPS estimate?
Gossamer Bio’s EPS estimate is -0.12.
How many shares outstanding does Gossamer Bio have?
Gossamer Bio has 488,846,700 shares outstanding.
What happened to Gossamer Bio’s price movement after its last earnings report?
Gossamer Bio reported an EPS of -$0.2 in its last earnings report, missing expectations of -$0.166. Following the earnings report the stock price went down -43.529%.
Which hedge fund is a major shareholder of Gossamer Bio?
Currently, no hedge funds are holding shares in GOSS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Gossamer Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$5.32 (1082.22% Upside)
$5.32 (1082.22% Upside)
Blogger Sentiment
Bullish
GOSS Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 3.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▲ 0.7%
Last 30 Days ▼ 1.7%
Last 30 Days ▼ 1.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-86.53%
12-Months-Change
Fundamentals
Return on Equity
174.85%
Trailing 12-Months
Asset Growth
-54.06%
Trailing 12-Months
Company Description
Gossamer Bio
Gossamer Bio, Inc. operates as a U.S.-based, clinical-stage biopharmaceutical company. Its primary objective is to discover, acquire, advance, and market novel therapeutic solutions, specifically addressing conditions within immunology, inflammatory diseases, and oncology. The company's pipeline highlights several key drug candidates: GB002: An inhaled small molecule designed to inhibit platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT, currently being developed for pulmonary arterial hypertension. GB004: An oral, gut-targeted small molecule in development for treating inflammatory bowel disease. GB5121: An oral, irreversible covalent small molecule that targets Bruton's Tyrosine Kinase (BTK), intended for primary central nervous system lymphoma. GB7208: Another oral small molecule BTK inhibitor, under investigation for multiple sclerosis. To support its drug development initiatives, Gossamer Bio has forged strategic licensing partnerships. It holds agreements with Pulmokine, Inc. for the advancement and commercialization of GB002 and its associated backup compounds. Additionally, the company collaborates with Aerpio Pharmaceuticals, Inc. regarding GB004 and related chemical entities. Founded in 2015, the enterprise was initially known as FSG, Bio, Inc. before rebranding as Gossamer Bio, Inc. in 2017. Its corporate headquarters are situated in San Diego, California.
GOSS Company Deck
GOSS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mixed but constructive picture: clinically meaningful efficacy signals (including a traditional statistical threshold for 6MWD), supportive mechanistic CT FRI data across multiple lung compartments with clinical correlations, and decisive capital actions (debt reduction plan and cost containment) to preserve runway and focus on an NDA path. Counterbalancing these positives were key execution risks — the primary endpoint did not meet the prespecified alpha, a substantial workforce reduction was implemented, cash runway is short ($99M to Q1 2027), and the debt exchange depends on high noteholder participation and involves tradeoffs. Overall, the tone is cautious and pragmatic, emphasizing strengthened conviction in the program but acknowledging material near-term financial and regulatory risks.View all GOSS earnings summariesGOSS Stock 12 Month Forecast
Average Price Target
$5.32
▲(1082.22% Upside)
Technical Analysis
Ownership Overview
1.86% Insiders
3.67% Mutual Funds
12.39% Other Institutional Investors
76.68% Public Companies and Individual Investors